Anticancer monoclonal antibody A33 (Ludwig Institute for Cancer Research)

N/A

Report date: 2025/10/20 14:43:38

Base Information

Drug NameAnticancer monoclonal antibody A33 (Ludwig Institute for Cancer Research)

Drug Alias NamehuA33 antibody131I-huA33131I-huAb A33

ClassificationRadiation-emitting products > Nuclides > Iodine > 131IRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates +[4]

Mechanisms of ActionIonising radiation emittersCell surface A33 antigen inhibitors

TargetsCell surface A33 antigen

Therapy Area/IndicationsColorectal Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryAustralia

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesLudwig Institute For Cancer Research

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesLudwig Institute For Cancer Research

Active IndicationsN/A

Inactive IndicationsColorectal Neoplasms

Other Information

ATC CodeN/A